Majority Of Claims In EpiPen Stock-Drop Suit Allowed To Proceed, Judge Rules

Mealey's (April 9, 2020, 2:21 PM EDT) -- NEW YORK — A federal judge in New York on April 6 ruled that lead plaintiffs in a securities class action against drugmaker Mylan N.V. and certain of its current and former executive officers sufficiently pleaded that the defendants issued a series of misrepresentations pertaining to the company’s classification of its EpiPen product and concealed its involvement in an anti-competitive rebate scheme that allowed Mylan to inflate the price of EpiPen (In re Mylan N.V. Securities Litigation, No. 16-7926, S.D. N.Y., 20202 U.S. Dist. LEXIS 60563)....